Welcome to our dedicated page for Nutriband news (Ticker: NTRB), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Nutriband Inc (NTRB) is a pharmaceutical innovator focused on transdermal drug delivery systems and abuse-deterrent technologies designed to enhance medication safety. This page serves as the definitive source for official company announcements, financial updates, and strategic developments.
Investors and industry stakeholders will find timely updates on AVERSA technology advancements, regulatory milestones, partnership agreements, and product pipeline progress. Our curated news collection ensures access to verified information directly impacting Nutriband’s market position and contributions to opioid safety solutions.
Key content includes earnings reports, intellectual property updates, manufacturing collaborations, and research breakthroughs. Bookmark this page to monitor Nutriband’s progress in developing transdermal therapies that address critical public health challenges while maintaining compliance with global regulatory standards.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) reported financial results for the fiscal year ending January 31, 2023, highlighting a record revenue of $2.1 million, up 46% from the previous year. Key achievements include a favorable court verdict recovering 15% of total outstanding shares and the announcement of a Seven-for-Six Forward stock split. The company received patent allowance for its AVERSA™ technology in North America and partnered with Kindeva Drug Delivery for enhanced abuse-deterrent characteristics. Despite a net loss of $4.48 million (or $0.53 per share), down from $6.37 million in FY 2022, the results reflect significant operational progress. Research expenses increased to $0.98 million from $0.4 million, while SG&A expenses decreased slightly to $3.9 million. The company aims for commercial growth in 2023 and anticipates AVERSA™ to achieve annual sales between $80 million and $200 million.
Nutriband (NASDAQ:NTRB, NTRBW), recognized for its innovative transdermal solutions, is set to present at the Planet MicroCap Showcase: VEGAS 2023 on April 26, 2023, at 08:30 AM PST. CEO Gareth Sheridan will lead the presentation, followed by a Q&A session.
To join the live presentation, access the webcast here. For those interested in one-on-one investor meetings during the event in Las Vegas, registration is available here.
Nutriband is advancing its abuse deterrent fentanyl patch utilizing the patented AVERSA technology, aimed at mitigating drug misuse and exposure risks.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced a partnership with Kindeva Drug Delivery to advance the AVERSA™ Fentanyl formulation into commercial manufacturing. The AVERSA™ Fentanyl product utilizes Nutriband's proprietary abuse-deterrent technology and is projected to achieve peak U.S. sales between $80M and $200M. This collaboration aims to develop the first abuse-deterrent fentanyl patch, enhancing safety and accessibility for patients. The technology is supported by a robust intellectual property portfolio, with patents granted in multiple countries.
